AI assistant
SHIELD THERAPEUTICS PLC AGM Information 2022
7914_agm-r_2022-07-27_bfabc9de-c0dc-4504-b46a-66a50d248f82.html
AGM Information
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information 
RNS Number : 9724T
Shield Therapeutics PLC
27 July 2022
Shield Therapeutics plc
("Shield" or the "Company" or the "Group")
Results of 2022 General Meeting
London, UK, 27 July 2022: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company focused on the commercialization of Accrufer®/Feraccru® (ferric maltol), a novel, oral iron therapy differentiated from other conventional irons by its efficacy, well-tolerated formulation, and broad indication, announces the results of the voting for each of the resolutions as set out in the Notice of General Meeting 2022. The Board reports that resolution 1 passed as an ordinary resolution and resolution 2 was passed as a special resolution, full details are shown below.
The following table shows the votes cast on each resolution:
| VOTES FOR |
% | VOTES AGAINST | % | WITHHELD VOTES | |
| Resolution 1 | 99,787,138 | 98.39% | 1,637,425 | 1.61% | 182,500 |
| Resolution 2 | 99,786,288 | 98.38% | 1,638,275 | 1.62% | 182,500 |
Notes:
1. Number of shares in issue 216,192,462.
2. Details of the votes received on the resolutions are available on the Company's website: https://www.shieldtherapeutics.com/corporate-documents/.
3. Shield Therapeutics plc LEI: 213800G74QWY15FC3W71.
The formal loan documentation is currently being finalised with AOP Health International Management and is expected to be concluded shortly. An announcement will be made following execution of that documentation.
For further information please contact:
| Shield Therapeutics plc | www.shieldtherapeutics.com |
| Greg Madison, CEO | +44 (0) 191 511 8500 |
| Hans-Peter Rudolf, CFO | |
| Nominated Adviser and Joint Broker | |
| Peel Hunt LLP | |
| James Steel/Christopher Golden | +44 (0)20 7418 8900 |
| Joint Broker finnCap Ltd Geoff Nash/ George Dollemore/Alice Lane/Nigel Birks |
+44 (0)20 7220 0500 |
| Financial PR & IR Advisor | |
| Walbrook PR | |
| Lianne Applegarth/Alice Woodings | +44 (0)20 7933 8780 or [email protected] |
| Investor Contact (US Advisor) LifeSci Advisors, LLC John Mullaly |
+1 617 429 3548 or [email protected] |
About Accrufer®/Feraccru®
Accrufer®/Feraccru® (ferric maltol) is a novel, stable, non-salt based oral therapy for adults with iron deficiency, with or without anemia. Accrufer®/Feraccru® has a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about Accrufer®/Feraccru®, including the product label, can be found at: www.accrufer.com and www.feraccru.com
About Shield Therapeutics plc
Shield is a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol). The Group has launched Accrufer® in the US and Feraccru® is commercialized in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of Accrufer® / Feraccru® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. in the Republic of Korea, and with KYE Pharmaceuticals Inc. in Canada.
Accrufer®/Feraccru® has patent coverage until the mid-2030s
Accrufer®/Feraccru® are registered trademarks of the Shield Group
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
ROMUBVSRURUBUAR